Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025)
Monopar Therapeutics (MNPR) posted Cash from Financing Activities of -$384680.0 for Q4 2025, down 100.42% sequentially from $92.4 million in Q3 2025, and down 100.69% YoY from $56.1 million in Q4 2024.
Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Monopar Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at -$384680.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 100.69% year-over-year to -$384680.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $91.6 million (up 54.45% YoY) and the FY2025 annual result came in at $91.6 million, up 54.45% from the prior year.
- Cash from Financing Activities retreated to -$384680.0 in Q4 2025 per MNPR's latest filing, from $92.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $92.4 million in Q3 2025 and troughed at -$384680.0 in Q4 2025.
- A 5-year average of $8.2 million and a median of -$8845.5 in 2021 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 558897.68% in 2025, down 3094.32% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$7772.0 in 2021, then soared by 1885.09% to $138737.0 in 2022, then jumped by 141.14% to $334548.0 in 2023, then jumped by 16679.9% to $56.1 million in 2024, then slumped by 100.69% to -$384680.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$384680.0, $92.4 million, and -$316845.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -384,680.00 |
| Dec 31, 2025 | -384,680.00 |
| Sep 30, 2025 | 92.39 Mn |
| Sep 30, 2025 | 92.39 Mn |
| Jun 30, 2025 | -316,845.00 |
| Jun 30, 2025 | -316,845.00 |
| Mar 31, 2025 | -115,682.00 |
| Mar 31, 2025 | -115,682.00 |
| Dec 31, 2024 | 56.14 Mn |
| Dec 31, 2024 | 56.14 Mn |
| Sep 30, 2024 | -16,534.00 |
| Sep 30, 2024 | -16,534.00 |
| Jun 30, 2024 | -9,919.00 |
| Jun 30, 2024 | -9,919.00 |
| Mar 31, 2024 | 3.18 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 334,548.00 |
| Dec 31, 2023 | 334,548.00 |
| Sep 30, 2023 | 246,703.00 |
| Sep 30, 2023 | 246,703.00 |